ライフサイエンスコーパス: alirocumab

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 higher rate of injection-site reactions with alirocumab.

2 on in the rate of cardiovascular events with alirocumab.

3 analysis included 4974 patients (3182 taking alirocumab, 1174 taking placebo, 618 taking ezetimibe).

4 domized placebo-phase, double-blind study of alirocumab 150 mg administered subcutaneously every 2 we

5 randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous in

6 5 mg (a PCSK9 inhibitor); and uptitration to alirocumab, 150 mg.

7 eeks apart, followed by 5 doses of 150 mg of alirocumab, 2 weeks apart.

8 ge LDL-C <50 mg/dL (44.7%-52.6% allocated to alirocumab, 6.5% allocated to ezetimibe, and 0% allocate

9 Randomization was to alirocumab 75/150 mg every 2 weeks or control for 24 to

10 Alirocumab, a monoclonal antibody that inhibits proprote

11 Alirocumab, a monoclonal antibody to proprotein converta

12 Alirocumab, a PCSK9 antibody, markedly lowers LDL-C leve

13 holesale acquisition costs of evolocumab and alirocumab); adopted a health-system perspective, lifeti

14 taract incidence was observed between pooled alirocumab and control groups.

15 Alirocumab and evolocumab are monoclonal antibodies that

16 Alirocumab and evolocumab are monoclonal antibodies that

17 At week 24, the difference between the alirocumab and placebo groups in the mean percentage cha

18 nce of cardiovascular benefit for ezetimibe, alirocumab, and evolocumab positions these drugs as add-

19 [placebo or ezetimibe]; representing 4,029 [alirocumab] and 2,114 [control] double-blind patient-yea

20 Alirocumab decreased LDL-C and LDL-apoB by increasing ID

21 background statin (n = 4629) were pooled by alirocumab dose (75 or 150 mg every 2 weeks) and control

22 The alirocumab group, as compared with the placebo group, ha

23 Alirocumab had no effects on FCRs or PRs of very low-den

24 mechanistic studies of the Lp(a) lowering by alirocumab in humans have been published to date.

25 eductions with the PCSK9 monoclonal antibody alirocumab may be affected by background statin dose due

26 tation patients randomly assigned to receive alirocumab, mean percent reduction in LDL-C at 2 weeks w

27 le-blind treatment 8 to 104 weeks; n = 3,340 alirocumab, n = 1,894 control [placebo or ezetimibe]; re

28 In summary, alirocumab provided consistent LDL-C reductions and was

29 Alirocumab reduced ultracentrifugally isolated LDL-C by

30 na requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard rati

31 tin, 80 mg; add-on ezetimibe therapy; add-on alirocumab therapy, 75 mg (a PCSK9 inhibitor); and uptit

32 In alirocumab-treated patients, 839 (25.1%) achieved 2 cons

33 The increase in apo(a) FCR during alirocumab treatment suggests that increased LDL recepto

34 After all subjects received 8 weeks of alirocumab treatment, LDL-C was reduced by 73% from base

35 atients achieving LDL-C goals at Week 24 for alirocumab versus control (interaction P-values non-sign

36 Incidence of adverse events was similar for alirocumab versus control, except for a higher rate of i

37 The safety of alirocumab was evaluated in patients with at least 2 con

38 LDL-C levels <25 or <15 mg/dl on alirocumab were not associated with an increase in overa

39 Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum

40 ents within the ODYSSEY trials that compared alirocumab with controls (placebo/ezetimibe), mainly as

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。